QGEN
QIAGEN NV · NYSE
- Sector Health Technology
- Industry Medical Specialties
- Website qiagen.com
- Employees(FY) 6000
- ISIN NL0015001WM6
Performance
-2.81%
1W
+9.49%
1M
-2.02%
3M
+2.1%
6M
+2.7%
YTD
+6.12%
1Y
Profile
QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping, and gene regulation instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR solutions; and developed and configured OEM consumables. Further, the company provides predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.
Technical Analysis of QGEN 2024-12-20
Technical Scores and Rating
Moving Average Score
Oscillator Score
Technical Rating
Recent News & Updates
- 2024-12-16 09:40
- 2024-12-13 09:50
- 2024-12-13 08:04
- 2024-12-12 16:05
- 2024-12-12 11:30
- 2024-12-12 03:05
- 2024-12-09 08:14
- 2024-12-06 11:31
- 2024-12-05 17:37
- 2024-12-05 16:05
- 2024-12-05 07:46
- 2024-12-05 03:05
- 2024-11-29 11:24
Qiagen Plans to Open New Facility in Spain in 2026(MT Newswires)
- 2024-11-29 09:40
- 2024-11-29 07:38
- 2024-11-29 05:09
QIAGEN announces new site in Barcelona for QIAstat-Dx operations(Medical Device Network)
- 2024-11-28 10:51
QIAGEN introduces new custom tools for microbial analysis(Medical Device Network)
- 2024-11-28 07:44
- 2024-11-28 06:00
- 2024-11-27 17:00
- 2024-11-27 16:05
- 2024-11-27 03:05
- 2024-11-25 09:50
- 2024-11-22 09:20
- 2024-11-22 05:46
- 2024-11-13 11:18
- 2024-11-13 06:08
- 2024-11-12 16:05
- 2024-11-12 03:05
- 2024-11-11 09:15
Page 1 of 10
previousnext
Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.